United States · Investor

Amgen

Last cheque observed Mar 2019. Silence since then is not evidence of inactivity: our sources miss unannounced rounds.

QuietCorporate VC

Series BSeries CSeries ACrowdfundingFinanceBiotechnology

Cheques on record
0%of best year0cheques in 12 months, 45 on record
Since the last cheque2776days00hrs00min00sec
Median round$45MRounds led1 of 45Sole investor4 roundsExits4 from the portfolioMostly inUnited States, 88%
Pitch Amgen

Amgen highlights

  1. 01

    45 rounds on record

  2. 02

    Mostly Series B and Series C: 61% of its rounds

  3. 03

    Sole investor in 4 rounds, median $23M

  4. 04

    4 exits from the portfolio

What they do

Type
Corporate VC (from a list, unverified)
Cheque size
Not stated
Sectors
CrowdfundingFinanceBiotechnology
Based in
Thousand Oaks, United States
Cold pitches
Not stated

The record

Every round we can evidence, newest first45 appearances

  1. 2019

    2 rounds

  2. Mar
    Imago BioSciencesSeries B · US · FinSMEs$40MWith 6 others
  3. Feb
    AetionSeries B · US · FinSMEs$27MWith 7 others
  4. 2018

    6 rounds

  5. Nov
    QurAlisSeed · US · FinSMEs$5.5MWith 3 others
  6. Oct
    Oxford Nanopore TechnologiesGB · Endpts$66MSole investor
  7. Jun
    PrecisionSeries B · US · FinSMEs$110MWith 18 others
  8. Jun
    SutroSeries E · US · FinSMEs$85MWith 17 others
  9. May
    AkiliSeries C · US · FinSMEs$55MWith 4 others
  10. Feb
    Senti BiosciencesSeries A · US · FinSMEs$53MWith 9 others
  11. 2017

    6 rounds

  12. Dec
    Obsidian TherapeuticsSeries A · US · FinSMEs$50MWith 5 others
  13. Nov
    SyapseSeries D · US · FinSMEs$30MWith 8 others
  14. Oct
    Kymera TherapeuticsSeries A · US · FinSMEs$30MWith 1 other
  15. Oct
    ImmaticsSeries E · DE · FinSMEs$58MWith 3 others
  16. Apr
    Science 37Series C · US · FinSMEs$29MWith 5 others
  17. Jan
    SiteOne TherapeuticsSeries B · US · Genengnews$15MLed
  18. 2013

    4 rounds

  19. Dec
    Sutro BiopharmaSeries D · US · finsmes.com$26MWith 5 others
  20. Oct
    OpsonaSeries C · IE · finsmes.com$3.9MWith 8 others
  21. Apr
    OpsonaSeries C · IE · finsmes.com$43MWith 7 others
  22. Mar
    Theraclone SciencesSeries B · US · finsmes.com$8.0MWith 7 others
  23. 2012

    2 rounds

  24. May
    Sutro BiopharmaSeries C · US · finance.yahoo.com$17MWith 4 others
  25. Apr
    Miragen TherapeuticsSeries B · US · finsmes.com$20MWith 4 others
  26. 2011

    3 rounds

  27. Aug
    ArdelyxSeries B · US · ardelyx.com$30MWith 2 others
  28. Aug
    Oncofactor CorporationSeries A · US · onbiovc.com$2.1MWith 5 others
  29. Jan
    Acylin TherapeuticsSeries A · US · onbiovc.com$4.4MWith 3 others
  30. 2010

    5 rounds

  31. Nov
    Sutro BiopharmaSeries C · US · finsmes.com$37MWith 4 others
  32. Sept
    DecImmune TherapeuticsVenture · US · finsmes.com$3.2MWith 2 others
  33. Aug
    TetraLogic PharmaceuticalsSeries C · US · fiercebiotech.com$32MWith 7 others
  34. Jun
    Calistoga PharmaceuticalsSeries C · US · calistogapharma.com$40MWith 5 others
  35. Mar
    Theraclone SciencesSeries B · US · xconomy.com$1.5MWith 5 others
  36. 2009

    4 rounds

  37. Nov
    Trinity BiosystemsDebt · US · deals.venturebeat.com$7.5MWith 4 others
  38. Oct
    EpizymeSeries B · US · fiercebiotech.com$32MWith 4 others
  39. Jun
    Miragen TherapeuticsSeries B · US · biospace.com$4.0MWith 3 others
  40. May
    Calistoga PharmaceuticalsSeries B · US$30MWith 3 others
  41. 2008

    1 round

  42. Aug
    InteKrinSeries C · US · deals.venturebeat.com$19MWith 6 others
  43. 2007

    3 rounds

  44. Oct
    AllozyneSeries B · US · allbusiness.com$30MWith 4 others
  45. Jun
    Cutting Edge InformationSeries A · US · salesandmarketingnetwork.com$16MWith 2 others
  46. Mar
    Calistoga PharmaceuticalsSeries A · US · calistogapharma.com$21MWith 3 others
  47. 2006

    4 rounds

  48. Jul
    Trinity BiosystemsSeries B · US$21MWith 3 others
  49. Jun
    VLST CorporationSeries B · US · vlstcorp.com$55MWith 6 others
  50. May
    Viron TherapeuticsSeries A · CA · vironinc.com$20MWith 5 others
  51. May
    AvidiaSeries C · US · freshnews.com$44MWith 6 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

The team

We hold 48 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

What the register says

From the firm's own filings with the SEC, which it must file accurately by law

5+funds on filenumbered funds in its name

Exits from the portfolio

Companies it backed that were later bought or listed4 in all

PTC TherapeuticsListed$125MJun 2013
EpizymeListed$60MMay 2013
Calistoga PharmaceuticalsBought by Gilead Sciences$375MFeb 2011
AvidiaBought by Amgen$290MSept 2008

An exit counts when it came after the firm's first round in the company. From historical deal records.

Companies it bought

Acquisitions by the firm itself

Dezima Pharma$300MSept 2015
Onyx Pharmaceuticals$11BAug 2013
KAI Pharmaceuticals$315MApr 2012
Micromet$1.2MJan 2012
BioVex$1.0BJan 2011
Avidia$290MSept 2008
Alantos PharmaceuticalsUndisclosedJun 2007
Ilypsa$420MJun 2007

Who they invest alongside

The investors most often in the same rounds as Amgen. A count of rooms they were both in, not a relationship either has claimed.

ARCH Venture PartnersVC firm7rounds togetherAlexandria Real Estate EquitiesVC firm7rounds togetherAlta PartnersVC firm6rounds togetherMPM CapitalPrivate equity6rounds togetherHealthCare VenturesGrowth equity5rounds togetherOVP Venture PartnersVC firm5rounds togetherSkyline VenturesVC firm5rounds togetherFrazier Healthcare PartnersPrivate equity4rounds togetherNovartis Venture FundCorporate VC4rounds togetherLilly VenturesCorporate VC3rounds togetherMedImmune VenturesCorporate VC3rounds togetherSV Life SciencesVC firm3rounds together

Recently backed

The latest companies Amgen put money into.

Aetion$27M · Feb 2019QurAlis$5.5M · Nov 2018Oxford Nanopore Technologies$66M · Oct 2018Akili$55M · May 2018Senti Biosciences$53M · Feb 2018Obsidian Therapeutics$50M · Dec 2017

Quick answers about Amgen

What does Amgen invest in?

Amgen invests most often at Series B and Series C (61% of the rounds on record), in sectors such as Crowdfunding, Finance and Biotechnology.

How active is Amgen?

45 investments on record, 0 of them in the last 12 months, and it led 1. The most recent was in Mar 2019.

What has Amgen invested in recently?

Its most recent investments on record: Imago BioSciences (Series B, Mar 2019), Aetion (Series B, Feb 2019) and QurAlis (Seed, Nov 2018).

How big are Amgen's cheques?

The median round it joins is $45M.

Does Amgen lead rounds?

Sometimes: it led 1 of its 45 investments on record (2%).

Where does Amgen invest?

Most of the companies it backs are in the United States (88%) and Ireland (5%).

Is Amgen investing now?

No investments in the last 12 months; the latest was in Mar 2019.

Who does Amgen invest alongside?

Most often ARCH Venture Partners (7 rounds together), Alexandria Real Estate Equities (7 rounds together) and Alta Partners (6 rounds together).

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it